Ginkgo Bioworks Holdings (DNA) Stock Overview
Develops a platform for cell programming in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DNA Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ginkgo Bioworks Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.57 |
| 52 Week High | US$17.58 |
| 52 Week Low | US$5.00 |
| Beta | 1.55 |
| 1 Month Change | 18.00% |
| 3 Month Change | -2.79% |
| 1 Year Change | 66.30% |
| 3 Year Change | -87.39% |
| 5 Year Change | n/a |
| Change since IPO | -96.65% |
Recent News & Updates
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up
Oct 03
Ginkgo Bioworks: Structural Cost Issues Will Be Difficult To Resolve
Sep 02Recent updates
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up
Oct 03Ginkgo Bioworks: Structural Cost Issues Will Be Difficult To Resolve
Sep 02Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 31% Price Boost Is Out Of Tune With Revenues
Jun 25Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 28% But Its Business Is Yet to Catch Up
Apr 27
Biopharma Demand Will Boost Automation And Data Services
Shifting towards tools like Ginkgo Automation platform addresses biopharma AI data demand, enhancing revenue through diversification.These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat
Mar 012025 Is Make Or Break For Ginkgo Bioworks
Feb 27Revenues Not Telling The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Shares Rise 39%
Feb 13Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris' Path
Jan 30Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15Ginkgo Bioworks: Not Enough Progress
Nov 13Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Oct 04Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Shareholder Returns
| DNA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 2.4% | 6.3% | 2.0% |
| 1Y | 66.3% | 0.4% | 17.9% |
Return vs Industry: DNA exceeded the US Life Sciences industry which returned 0.4% over the past year.
Return vs Market: DNA exceeded the US Market which returned 17.9% over the past year.
Price Volatility
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 14.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DNA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 834 | Jason Kelly | www.ginkgo.bio |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.
Ginkgo Bioworks Holdings, Inc. Fundamentals Summary
| DNA fundamental statistics | |
|---|---|
| Market cap | US$752.12m |
| Earnings (TTM) | -US$315.19m |
| Revenue (TTM) | US$230.82m |
Is DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA income statement (TTM) | |
|---|---|
| Revenue | US$230.82m |
| Cost of Revenue | US$48.49m |
| Gross Profit | US$182.32m |
| Other Expenses | US$497.52m |
| Earnings | -US$315.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.69 |
| Gross Margin | 78.99% |
| Net Profit Margin | -136.56% |
| Debt/Equity Ratio | 0% |
How did DNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 13:44 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ginkgo Bioworks Holdings, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Matthew Sykes | Goldman Sachs |